Biotech | April 06, 2026
Enveda’s experimental oral therapy shows breakthrough results in atopic dermatitis trial
Safety was equally impressive. ENV-294 was well tolerated
Safety was equally impressive. ENV-294 was well tolerated
The patient, suffering from calcific severe aortic stenosis—a dangerous narrowing of the heart valve caused by calcium buildup—had run out of standard treatment options
Parliament clears reform bill replacing jail terms for procedural lapses with graded monetary penalties across key health laws
The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment
The approach, which could significantly reduce the number of rats used in certain dose-range finding studies
Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN
The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
Subscribe To Our Newsletter & Stay Updated
